LONDON – Following a total corporate makeover and a revamp of its technology, Realm Therapeutics plc has announced its rebirth with the filing of an FDA investigational new drug application (IND) for a phase II study of its lead product, PRO22, in atopic dermatitis and a promise to start a second phase II, in allergic conjunctivitis, later this year.